top of page
HOME
HOME
LEVERAGING AI AND DATA SCIENCE TO DRIVE ACCESS TO MEDICINES
We provide AI-powered data solutions that help unlock equitable access to medicines in five key European markets; France, Germany, Italy, Spain and the UK.
Our AI and analytics solutions provide unparalleled visibility of the access environment, helping pharma and healthcare organisations identify opportunities to improve access to life-changing innovations.
Anchor 1
Why You're Here
WE MAXIMISE THE VALUE OF MEDICINES
ValueBase is driven by a singular mission: to ensure all patients have timely access to the best treatments available, no matter where they live.
We partner with pharma companies to visualise the access environment and highlight disparities in target therapy areas. Our AI-powered data solutions provide a unique evidence-base to inform strategies that maximise the value of medicines.
The world’s biggest pharma companies use ValueBase as their data insights partner – helping them design agile access strategies that support every stage of the product lifecycle, from early asset to loss of exclusivity.
Together we’re unlocking equitable access to medicines.
We specialise in AI-powered data solutions that help pharma companies identify and manage barriers to access – allowing them to design strategies based on real-world indicators and meaningful analogues. We also partner with health providers and policymakers to highlight gaps in access that need addressing.
Our descriptive and predictive AI-led solutions can track the access environment in five key European markets – France, Germany, Italy, Spain and the UK – mapping the changes driving regional access in each country, across formularies, guidelines or contracts. Insights can be combined with your latest prescribing data to give you critical insights around availability and impact.
We can also help you see into the future. Our AI solutions – powered by the highest quality longitudinal data out there – enable next generation predictive modelling, allowing companies to pre-empt (and plan for) negative access events with confidence. Now you really can predict the predictable and see the unseeable.
SEE THE UNSEEABLE
How We Help
Anchor 2
Our Solutions
THE COMPLETE PICTURE. ALL DAY, EVERY DAY
Our digital access tools provide the complete picture of availability, access and adoption of medicines in five key European markets.
We monitor the market 24/7, allowing businesses to detect and respond to change as it happens or review trends over time.
Our solutions empower brand teams with real-world intelligence that drives competitive advantage – and helps unlock equitable access to medicines.
Anchor 6
Formulytics tracks medicines formularies all day, every day – detecting updates the day they happen.
It allows businesses to monitor product availability and adoption, benchmark competitors, identify early adopters and respond to gaps in access. Formulytics makes the invisible visible. Quickly and accurately.
In some countries, guidelines sit separately to formularies.
Guidelight can provide a real-time view of local guidelines. Once a therapy area is coded, it monitors the environment 24/7, capturing updates for every published guideline and every locality.
Our FOI system monitors updates to unpublished guidelines too, giving customers a 360° view of positioning, prescribing options and recommendations.
Our proprietary indexing tool, the Availability Index is a standard measure of access for every product that allows companies to compare the access availability of products within a locality and across regions.
It takes account of the initiating prescriber, the positioning and restrictions noted within the relevant access documents.
AI Solutions
AI Solutions
AI-POWERED MARKET ACCESS SOLUTIONS
In a complex and competitive healthcare landscape, success depends on more than clinical efficacy - it demands data-driven insights, adaptive strategies, and real-time decision-making. Our suite of AI-enabled tools empowers pharmaceutical teams to accelerate market access, optimise value communication, and stay ahead in a fast-evolving environment.
UNLOCK FASTER, SMARTER MARKET ACCESS ACROSS THE PRODUCT LIFECYCLE
Product Launch Predictions
Launching a new pharmaceutical product is high-risk, high-reward - and timing, market dynamics, and execution make all the difference. Our AI-driven predictive model empowers you to forecast performance, mitigate risks, and optimise every step of your launch strategy with confidence and precision.
• Model uptake scenarios across UK, Spain, Germany, France and Italy
• Highlight early adopters and laggards to inform your resourcing strategy
• Bespoke modelling to highlight high and low value contracts and pricing agreements
Post Launch Optimisation
Launching a new product? The past holds the key to your future success.
The launch is just the beginning. To maximise product value over time, pharma leaders must continuously adapt to shifting market dynamics, competitive pressures, and real-world performance. Our post-launch predictive model empowers you to monitor, forecast, and optimise your brand’s trajectory - before challenges become losses.
• Predictions for early signs of performance deviation for proactive intervention
• Model the impact of new indications and presentations
• Recommendations for adjustments in resourcing to maximise access potential
LoE Predictive Models
As your product nears Loss of Exclusivity (LoE), early accurate insight into competitive threats and market shifts can mean the difference between protecting your brand or losing ground. Our AI-powered LoE Predictive Model gives you the foresight to act decisively - months or even years ahead of LoE.
• LoE performance projects for the next 5 years post LoE
• Highlights early predicted losses to access, so you can proactively prevent them
• Tailored simulations for post-LoE scenarios based on policy changes,
market dynamics, and competitor activities
LET'S TRANSFORM MARKET ACCESS TOGETHER
Whether you're preparing for early pre-launch engagement, post-launch optimisation, or LoE planning our AI-driven tools give your teams the clarity, agility, and foresight to navigate access challenges—smarter and faster.
Protect your assets, sharpen your strategy, and stay ahead of the curve. Talk to us to see how our LoE Predictive Model can help you make better decisions - before your competitors do.
Whre We Hep
IF IT’S A QUESTION OF ACCESS, WE'LL HELP YOU FIND THE ANSWERS
Pharma companies use ValueBase to answer the big questions. Our solutions track the access environment over time, unlocking rich datasets that inform decision-making at every stage of the product lifecycle.
In-market multidisciplinary teams rely on our data insights to support:
• Commercial/brand strategy
• Business development
• Forecasting
• Product launch
• Strategy adjustment/refinement
• Loss of Exclusivity (LoE) planning
Click the buttons below to see some of the questions we can help you answer in 3 core areas:
Where We Help
Anchor 5
NHS Solutions
INTELLIGENCE THAT POWERS
INTEGRATED NEIGHBOURHOOD TEAMS
As Integrated Neighbourhood Teams (INTs) become the cornerstone of community-based care, the need for timely, connected, and actionable data has never been greater. SYNAPSE is the smart solution designed to meet that need - bringing together multiple published data sources relevant to revenue and broader operational management in primary care.
YOUR DATA, UNITED
SYNAPSE seamlessly bridges the gap between fragmented data sets, integrating information from across public health, clinical performance, funding streams, demographic insights, and more. No more jumping between dashboards or struggling to align reports - SYNAPSE brings it all into one intuitive platform.
INSIGHTS THAT DRIVE ACTION
In response to the NHS's ongoing transformation, including the shift towards neighbourhood health services and the integration of multidisciplinary teams, SYNAPSE is evolving to support these changes.
DESIGNED FOR PRIMARY CARE. BUILT FOR THE FUTURE.
SYNAPSE was built with frontline needs in mind. It’s the tool for primary care leaders, finance teams, and INT coordinators who need to turn data into decisions and insight into impact.
ADAPTING TO NHS TRANSFORMATION
In response to the NHS's ongoing transformation, including the shift towards neighbourhood health services and the integration of multidisciplinary teams, SYNAPSE is evolving to support these changes.
SYNAPSE is designed to align with the NHS's vision of delivering more care at home or closer to home, improving access, experience, and outcomes for patients. By providing integrated data and insights, SYNAPSE empowers INTs to navigate the complexities of these reforms and deliver coordinated, patient-centred care.
SEE THE BIGGER PICTURE.
ACT WITH CONFIDENCE. DELIVER BETTER CARE.
NHS Solutions
How We Do It
DIGITAL INGENUITY WITH THE HUMAN TOUCH
Public information on formularies and guidelines is disparate, variable and hard to find. The volume of change each day is vast. If you want to monitor the environment, you need automation to remove the heavy lifting so humans can focus on the “smart things".
Our AI-led solutions combine smart data engineering with the human experience. Our systems are built in-house by our engineers using AI, machine learning and automation solutions to drive our innovations. Information is reviewed and cleansed by experts, then moved into data systems that fire our innovations.
It’s human experience and artificial intelligence combined to create insight that helps unlock access to medicines.
Anchor 7
Our Tools
NEXT GENERATION ACCESS SOLUTIONS. ENGINEERED HERE.
ADA is our custom-designed artificial intelligence tool that works in the background of the business 24/7. ADA is programmed to look through millions of rows of UK formulary data and guidelines every day to flag changes for our data managers to investigate. Inspired by Ada Lovelace –who published the first known computer algorithm – she’s one of the team.
ANA is ADA’s twin sister – her focus is on formularies in markets outside the UK.
Our web scraping system for extracting published data from formularies/access sources. Designed in-house by our data engineers.
Built in-house, Humanae is web resource monitoring software for formulary information.
Anchor 8
Anchor 9
VALUE STORIES
Access all areas: a short guide to formulary visibility
EXPLAINER
May 2024
NICE rejects Enhertu in breast cancer – but a NICE recommendation doesn’t guarantee access
BLOG
March 2024
4 for 24: the trends that could shape access in 2024
BLOG
January 2024
Not NICE: why are women being deprived access to life-changing cancer treatments?
ANALYSIS
March 2023
NICE-recommended lung cancer treatments still absent from formularies
ANALYSIS
August 2023
Access to medicines consistently fails to meet mandatory targets in the UK
ANALYSIS
July 2023
FEATURE
NICE - but not enough. Why evidence is better than assumption when executing your access strategy
"NHS not ready for new Alzheimer's drugs lecanemab and donanemab, warns charity"
OPINION
February 2024
Obesity & diabetes markets are growing – but launch strategies are variable
ANALYSIS
November 2023
Patients are being denied access to EAMS-listed medicines
ANALYSIS
February 2023
Head and neck cancer patients missing out on life-extending treatment
ANALYSIS
July 2023
PwC report exposes glaring disparities in UK healthcare
ANALYSIS
December 2022
FEATURE
Mapping at launch:
Time to update the satnav
VPAG is on the money – data is key to tackling unwarranted variation in adoption of medicines
ANALYSIS
February 2024
CVD: are patients being denied access to life-changing medicines?
ANALYSIS
September 2023
Has Postcode Prescribing got its own category on NHS formularies?
ANALYSIS
April 2023
Endometrial cancer treatment granted EAMS status – but will patients get early access?
ANALYSIS
July 2023
Health inequity?
Let’s get it out of here
ANALYSIS
November 2022
VIDEO
Mastering the maze of UK formularies
FEATURE
Double your sales at launch? Here's how
ANALYSIS
A million patients with stroke, diabetes, asthma or kidney disease are missing out on approved medicines
VIDEO
Tracking formularies:
Five Top Tips
Our Values
PURPOSE-DRIVEN, VALUES-BASED
Why do we do it? That’s simple. We’re driven by a shared purpose:
To ensure medicines are available and accessible to all appropriate patients.
That’s your goal. It’s our goal too.
To achieve it, we adopt a values-based culture. Here are our values.
Anchor 10
Client-centred, Patient-first
We take every opportunity to delight our customers – and
our customers’ customers
Equitable
We advocate equitable access to opportunities (and medicines)
Collaborative and Agile
We work together in highly effective cross-functional and agile teams
Supportive
We look out for each other. We’re compassionate, empathetic and respectful
Flexible
We welcome and adapt to change and uncertainty
Scalable
We engender a growth mindset
Anchor 11
OUR MANAGEMENT TEAM
Karen Westaway
Chief Executive Officer
Caroline Shortland
Chief Operating Officer
Wilf Iliffe
Director of Analytics
Paula Baxter
Commercial Excellence Director
Robyn Nowers
Transformation Director
Arby Saboonchian
Customer Experience Director
CONTACT US
To find out how you could bolster your access strategy using ValueBase’s tools and analytics – or arrange a demonstration – get in touch.
Simply drop us a note using the web form right here.
Email us on enquiries@thevaluebase.com
Or connect with us on LinkedIn
Anchor 12
bottom of page